Rhegmatogenous Retinal Detachment Clinical Trial
Official title:
Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment.
This study investigates the effectiveness of a simple treatment to prevent proliferative vitreoretinopathy (PVR). Intraoperative intravitreal 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) is used as a prophylactic therapy in high-risk patients with primary rhegmatogenous retinal detachment (RRD). Our major motivation is to reduce the incidence of PVR in the group that receives the trial drug.
Proliferative vitreoretinopathy (PVR) is a common cause for postoperative failure after vitreoretinal surgery for primary RRD. There is no standard-therapy to prevent PVR. Several attempts using chemotherapeutic agents have been undertaken to prevent this proliferation-process, but none of these was introduced into routine clinical practice. Until recently, it has been challenging to identify patients with high risk for postoperative PVR formation. This is especially important, because in this trial treatment with the trial drug will be restricted to patients at high risk for PVR only. Patients are assigned to the following treatment arms (1:1): (A) Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV) in high-risk patients for proliferative vitreoretinopathy (PVR) with primary rhegmatogenous retinal detachment (RRD). Versus: (B) Routinely used intraocular infusion with balanced salt solution (BSS) during routine PPV. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04403750 -
Combined Laser-surgical Technology of RRD Treatment
|
N/A | |
Not yet recruiting |
NCT04520789 -
Early Prevention Strategies of Severe Proliferative Vitreoretinopathy Base on Precision Diagnosis of Single Cell Sequencingvitreoretinopathy
|
N/A | |
Recruiting |
NCT04571788 -
Treating Rhegmatogenous Retinal Detachment by Foldable Capsular Buckle
|
||
Recruiting |
NCT01845571 -
Retinal Detachment - Demographic and Clinical Survey
|
||
Completed |
NCT04891991 -
Intravitreal Infliximab for Proliferative Vitreoretinopathy
|
Phase 2 | |
Recruiting |
NCT02871531 -
Pneumatic Retinopexy Versus Vitrectomy for Retinal Detachment in Patients With Extended Criteria
|
N/A | |
Completed |
NCT00757536 -
Primary Vitrectomy With Endolaser or Encircling Band for Rhegmatogenous Retinal Detachment
|
N/A | |
Active, not recruiting |
NCT00370201 -
Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment
|
Phase 3 | |
Completed |
NCT00345007 -
Macular Function After Scleral Buckle
|
N/A | |
Recruiting |
NCT05331664 -
Dropless Pars Plana Vitrectomy Study
|
Phase 4 | |
Completed |
NCT02841306 -
Ursodeoxycholic Acid for Rhegmatogenous Retinal Detachment
|
Phase 1 | |
Not yet recruiting |
NCT02185469 -
Corneal Endothelial Cell Loss After Pneumatic Retinopexy for the Repair of Primary Rhegmatogenous Retinal Detachment
|
N/A | |
Not yet recruiting |
NCT01647373 -
Axial Length Change in Eyes Treated by Silicone Sponge Scleral Buckling
|
N/A | |
Completed |
NCT01068379 -
Clinical Trial of Cryotherapy Versus Postoperative Laser Photocoagulation
|
Phase 3 | |
Not yet recruiting |
NCT06468397 -
Acute Retinal Detachment Repair With the iSeelr^TM Retinal Detachment Repair System
|
N/A | |
Not yet recruiting |
NCT06425419 -
The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy
|
Phase 1 | |
Recruiting |
NCT06056596 -
Lamivudine and Plasma Markers of Inflammation in Retinal Detachment
|
Early Phase 1 | |
Completed |
NCT01343134 -
Anatomical and Functional Macular Changes in Retinal Detachment
|
N/A | |
Recruiting |
NCT05588037 -
Combined Vitrectomy and Femtosecond Laser-assisted Cataract Surgery
|
N/A | |
Completed |
NCT03542162 -
Healaflow Patch for the Treatment of Rhegmatogenous Retinal Detachment
|
N/A |